Seoul National University Hospital Clinical Trials Center
Seoul, 110-744, South Korea
NCT Number: NCT01264224
1. Primary Objective:
* To evaluate safety and tolerability of single and multiple oral dosing of PAC-14028 in healthy male volunteers. 2. Secondary Objective:
* To evaluate pharmacokinetics and pharmacodynamics of single and multiple oral dosing of PAC-14028 in healthy male volunteers.
Looking for future studies?
Notify Me20 year–45 year
Male
Interventional
Phase 1
Seoul, 110-744, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-BMI (kg/m^2) = weight(kg) /{height(m)}^2
Exclusion criteria
tablets, oral administration, single/multiple dosing, dose escalation
AE incidence pattern, abnormal findings in vital sign, ECG test, and clinical lab tests
Amorepacific Corporation
Industry
A Dose-block Randomized, Double-blind, Placebo-controlled Single/Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of PAC-14028 After Oral Administration in Healthy Male Volunteers.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07374406
Healthy
Jeonju, South Korea
View Trial DetailsNCT07365865
Deficient Keratinized Mucosa, Healthy
Cairo, Egypt
View Trial DetailsNCT04849923
Healthy
Winterthur, Canton of Zurich, Switzerland
View Trial DetailsNCT06744517
Behavior, Healthy
Toronto, Ontario, Canada
View Trial Details